Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationEBIATLong-Term Debt IssuancesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - OtherShares IssuedShares OutstandingShares Outstanding
Ratios

Arcus Biosciences (RCUS) Accumulated Depreciation & Amortization (2017 - 2025)

Arcus Biosciences has reported Accumulated Depreciation & Amortization over the past 9 years, most recently at $10.0 million for Q4 2025.

  • For Q4 2025, Accumulated Depreciation & Amortization changed 0.0% year-over-year to $10.0 million; the TTM value through Dec 2025 reached $10.0 million, changed 0.0%, while the annual FY2025 figure was $10.0 million, 0.0% changed from the prior year.
  • Accumulated Depreciation & Amortization for Q4 2025 was $10.0 million at Arcus Biosciences, roughly flat from $10.0 million in the prior quarter.
  • Over five years, Accumulated Depreciation & Amortization peaked at $10.0 million in Q4 2024 and troughed at $4.0 million in Q4 2021.
  • A 5-year average of $7.6 million and a median of $8.0 million in 2023 define the central range for Accumulated Depreciation & Amortization.
  • Biggest five-year swings in Accumulated Depreciation & Amortization: plummeted 72.0% in 2021 and later skyrocketed 50.0% in 2022.
  • Year by year, Accumulated Depreciation & Amortization stood at $4.0 million in 2021, then skyrocketed by 50.0% to $6.0 million in 2022, then skyrocketed by 33.33% to $8.0 million in 2023, then rose by 25.0% to $10.0 million in 2024, then changed by 0.0% to $10.0 million in 2025.
  • Business Quant data shows Accumulated Depreciation & Amortization for RCUS at $10.0 million in Q4 2025, $10.0 million in Q4 2024, and $8.0 million in Q4 2023.